Physician Assistant, Medical · Shawnee, OK
NPI
1487747713
Since 2006
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3315 Kethley Rd
Shawnee, OK, 74804
Phone (405) 273-5801
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
1,807 services
Medicare patients, 2024
509
Average age 73
Drug cost, 2024
$1.9M
9,972 prescriptions
Company payments, 2025
$994
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark L Davis was code 99214 (office e&m - established), 796 times for 439 patients. In total Mark L Davis billed 1,807 services in 24 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-08-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 796 | 439 | $56.52 | $45K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 697 | 400 | $10.53 | $7,341 |
| 99215 Office E&M - Established | Facility | 104 | 91 | $81.56 | $8,482 |
| 99204 Office E&M - New | Facility | 80 | 80 | $76.51 | $6,120 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Facility | 68 | 68 | $105.87 | $7,199 |
By year: 2022 $70K for 1,146 services; 2023 $88K for 1,273 services; 2024 $77K for 1,807 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark L Davis prescribed most often to Medicare patients was Montelukast Sodium, with 824 prescriptions and refills. In total Mark L Davis wrote 9,972 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 824 | 1,789 | 224 | $11K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 807 | 1,010 | 179 | $644K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 620 | 762 | 237 | $20K |
| Prednisone Generic | 351 | 421 | 174 | $1,881 |
| Azithromycin Generic | 310 | 398 | 120 | $5,125 |
| Fluticasone Propionate Generic | 268 | 443 | 92 | $6,161 |
| Omeprazole Generic | 247 | 557 | 69 | $5,973 |
| Pantoprazole Sodium Generic | 226 | 532 | 70 | $2,710 |
| Levothyroxine Sodium Generic | 220 | 623 | 56 | $2,569 |
| Gabapentin Generic | 218 | 461 | 54 | $4,070 |
| Famotidine Generic | 217 | 504 | 63 | $3,352 |
| Amlodipine Besylate Generic | 210 | 551 | 57 | $1,114 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 190 | 267 | 63 | $33K |
| Lisinopril Generic | 161 | 446 | 43 | $1,608 |
| Atorvastatin Calcium Generic | 151 | 449 | 49 | $1,681 |
Brand drugs: 2,602 claims; generic drugs: 7,353 claims; opioid claims: 114.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark L Davis $994 ($994 in general payments such as food, travel and fees) from 12 companies. The largest payer was GlaxoSmithKline, LLC. with $200.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 20 | $200 |
| Baxter Healthcare BAX | 10 | $158 |
| Viatris Specialty LLC | 10 | $155 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $152 |
| Amgen Inc. AMGN | 4 | $78.4 |
| Genzyme Corporation SNY | 3 | $67.35 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $55.7 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40.33 |
| Verona Pharma, Inc. VRNA | 2 | $29.85 |
| Philips North America LLC PHG | 2 | $27.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.